NCT02332902View on ClinicalTrials.gov

Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Neurofibromatosis 1
Interventions
DRUG

Everolimus

Everyone in the study will receive Everolimus at a starting dose of 10 mg daily and will be adjusted up or down by 2.5 mg at 2 week intervals to attain a trough concentration of 5-15 ng/ml

Trial Locations (1)

77030

The University of Texas Health Science Center at Houston, Houston

All Listed Sponsors
collaborator

Texas Neurofibromatosis Foundation

UNKNOWN

lead

The University of Texas Health Science Center, Houston

OTHER

NCT02332902 - Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T | Biotech Hunter | Biotech Hunter